APCOM Trial
@APCOMTrial
Followers
51
Following
361
Media
3
Statuses
246
Activating #PrimaryCare #COPD Patients with #Multimorbidity (APCOM) Trial - a global-first, #MRFF/@NHMRC-sponsored pragmatic clinical trial in primary care.
Australia
Joined June 2021
The baseline findings poster of the #APCOMTrial, presented at the 2025 @tsanz_thoracic Scientific Meeting, can be downloaded here: https://t.co/HbCFUayyab
#COPD #multimorbidity #primaryhealthcare
drive.google.com
Our poster on baseline findings of the @APCOMTrial is up at the @tsanz_thoracic #tsanzsrsasm2025. Please visit poster board 97 during the Poster Session at 4 15pm today. #COPD #multimorbidity #primaryhealthcare #APCOMTrial
0
2
2
If you are interested in #multimorbidity then you might want to read our new editorial just out in @bmj_latest today: https://t.co/f6TGK5vWJT
0
4
6
Qualitative evaluation of the #APCOMProgram found acceptance by patients, PNs and GPs: https://t.co/XlTdbGOOhL Funding and standards for #selfmanagement education in general practice are needed. #COPD #multimorbidity #primaryhealthcare @HassanHosseinza @MohanaSekaran @nickzwar
link.springer.com
BMC Primary Care - Chronic obstructive pulmonary disease (COPD) is often associated with comorbidities, which further complicates the impact of the disease. However, most self-management support...
0
2
2
After 9 years of work, our new @ATSBlueEditor paper is out, showing that in utero maternal smoke leaves lasting scars on lung health, and identifies CC16 as the first reliable biomarker of lung health across the lifespan. #cureCOPD
https://t.co/Ctbz7cvgnH
6
22
76
World COPD Day, November 19, 2025 - The goal of this year’s campaign is to emphasize that shortness of breath is a symptom that should prompt patients and healthcare providers to consider a diagnosis of COPD.
1
2
3
World COPD Day, November 19, 2025 - The goal of this year’s campaign is to emphasize that shortness of breath is a symptom that should prompt patients and healthcare providers to consider a diagnosis of COPD.
0
4
4
🆕 The skin condition #panniculitis is a rare manifestation of #alpha1. The lack of evidence makes it difficult to treat, and those affected often experience diagnostic delay and significant symptoms. You can read more in this paper by @ReemAlluhibi from my lab. @AlphaFriend
Proud to share the first publication from my PhD ✨! This study - initiated from the insight of a patient living with alpha-1 panniculitis explores the lived experience of this rare and painful condition. 📌
2
3
7
The International Cardiovascular & Respiratory Alliance, ICRA, is a global group that I founded & co-chair with Prof M Bhutani. We represent healthcare professionals, academics & patients from >40 countries. To join (free) email: icracomms@optimumpatientcare.org
2
10
21
In theory, #DPP-1 inhibitors should work any neutrophilic #airway conditions such as #COPD. The key is finding the #neutrophilic #COPD patients.
European Respiratory Review: DPP-1 inhibitors are a novel treatment targeting neutrophilic inflammation https://t.co/SlsXfq5S0W
1
9
27
Wonderful collaboration with Sadan Taher, @alta_schutte, @ProfHurst and @cpgale3 on this global-first systematic review: https://t.co/NK4FrkNdR4
#COPD #HTN #CVD #multimorbidity #publichealth
journals.sagepub.com
Background: Chronic obstructive pulmonary disease (COPD) and hypertension are prevalent public health burdens, with hypertension often co-existing in up to 65% ...
In this review by Sameera Ansari, @ProfHurst , et al we found “limited & inconsistent evidence available for managing concomitant #COPD & #hypertension” https://t.co/L3Uv0G41QP
0
4
6
Feeling of satisfaction completing the Gold Coast Marathon today with one of our children. I’ve now had the joy of doing an event with all four of them as well as one grandchild. Marathons are no longer about medals or times. It’s about the joy of the experience! #copd
9
5
27
#COPD & the Management of Cardiopulmonary Risk https://t.co/8bEWPOEheq
dovepress.com
To establish UK consensus statements and a clinical pathway for managing cardiopulmonary risk in patients with Chronic obstructive pulmonary disease
1
3
7
A landmark moment for global lung health! #WHA78 ERS and @europeanlung applaud adoption of historic lung health resolution on “Promoting and prioritizing an integrated lung health approach” at the 78th World Health Assembly. Read more: https://t.co/geHv8ms0NM
0
4
6
Come and take me on in our #ATS2025 #COPD bike challenge. Can you beat the #copdathlete Find me at the Inogen booth #326
2
7
20
Glad to have presented last week's @Woolcockmedical Friday seminar about my innovative research program on managing #COPD in the context of #multimorbidity. The seminar recording is available here: https://t.co/Uh8rty0o1r
#publichealth #primaryhealthcare
macquarie.zoom.us
Zoom is the leader in modern enterprise video communications, with an easy, reliable cloud platform for video and audio conferencing, chat, and webinars across mobile, desktop, and room systems. Zoom...
0
2
5
Managing cardiopulmonary risk in #COPD: expert insight & consensus
hospitalhealthcare.com
Professor Chris Gale discusses a consensus statement on strategies for the identification and management of cardiopulmonary risk in COPD.
0
5
24
World first! @MHRAgovuk approves the first pMDI for #COPD with a new propellant having near-zero global warning potential. pMDIs are essential medicines. Kudos to all involved. A good day for people living with COPD, and the 🌎. https://t.co/btNqZtbCoq
gov.uk
As with all medicines, the MHRA will continue to monitor the safety and effectiveness of Trixeo Aerosphere
2
12
29
Phenotyping PH in COPD is a major challenge in respiratory medicine. Grateful for the great collaboration with the Strasbourg team. Our study is now out in ERJ Open Research @pulmotension
@InsermU999
@SPLF_SocPneumo
@HTaPFrance
https://t.co/RXKom4z1CC
1
16
40
Honoured to have contributed to the global-first position statement on reducing cardiopulmonary risk in people with #COPD. Thank you for the opportunity, @cpgale3 and @ProfHurst. #CVD #multimorbidity
academic.oup.com
AbstractAims. Cardiovascular disease is a common comorbidity in chronic obstructive pulmonary disease. Yet, cardiovascular disease and risk are underdiagno
With many thanks to my Global working Group… Identification & management of cardiopulmonary risk in patients with COPD: a multidisciplinary consensus & modified Delphi study #cardiovascular #COPD
https://t.co/b6C5WoHN1Q
1
2
3